Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29236563 | 0.79 | CLK1 (0.55) | CLK1BACE1NOS1TDP1GPR35 | |
| SCHEMBL3786029 | 0.79 | CLK1 (0.46) | CLK1BACE1NOS1TDP1GPR35 | |
| SCHEMBL395905 | 0.79 | TDP1 (0.50) | CLK1BACE1NOS1TDP1GPR84 | |
| SCHEMBL28784022 | 0.79 | CLK1 (0.46) | CLK1BACE1NOS1TDP1GPR35 | |
| SCHEMBL29811443 | 0.79 | TDP1 (0.50) | CLK1BACE1NOS1TDP1GPR84 | |
| SCHEMBL1943316 | 0.79 | CLK1 (0.46) | CLK1BACE1NOS1TDP1GPR35 | |
| SCHEMBL14168306 | 0.78 | CLK1 (0.43) | CLK1BACE1CA1CA2NOS1 | |
| SCHEMBL29956050 | 0.77 | CYP2A6 (0.57) | CLK1BACE1NOS1TDP1GPR35 | |
| SCHEMBL3208591 | 0.77 | CYP2A6 (0.57) | CLK1BACE1NOS1TDP1GPR35 | |
| SCHEMBL2029263 | 0.76 | TSHR (0.46) | CLK1BACE1NOS1TDP1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184567-B | Process for preparing 3-haloindole derivatives | 常州工程职业技术学院 | 2025-02-18 | — | — | CN | disclosed |
| CN-118184567-A | Process for preparing 3-haloindole derivatives | 常州工程职业技术学院 | 2024-06-14 | — | — | CN | disclosed |
| US-20220298141-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| EP-4017849-A1 | ENZYME INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
| CN-114286820-A | Enzyme inhibitors | 卡尔维斯塔制药有限公司 | 2022-04-05 | — | — | CN | disclosed |
| WO-2021032934-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| EP-0944621-B1 | 2-IMIDAZOLINYLAMINOINDOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | PROCTER & GAMBLE (US) | 2004-09-01 | — | — | EP | disclosed |
| US-6395764-B1 | NOSAL DECONGESTION, RESPIRATORY SYSTEM DISORDERS | THE PROCTER & GAMBLE COMPANY | 2002-05-28 | — | — | US | disclosed |
| US-6162818-A | 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists | THE PROCTER & GAMBLE COMPANY (US) | 2000-12-19 | — | — | US | disclosed |
| EP-0944621-A1 | 2-IMIDAZOLINYLAMINOINDOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998023610-A1 | 2-IMIDAZOLINYLAMINOINDOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298141-A1 | ENZYME INHIBITORS | SERPINB1, ACE, GAA | CLK1 4311/4885BACE1 47/4885CA1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.